"The voice for cancer physicians and their patients in Massachusetts."

FDA approves nertinib (Nerlynx) for metastatic HER2-Positive breast cancer

27 Feb 2020 7:13 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved neratinib (Nerlynx; Puma Biotechnology) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software